26 december 2010: Recent is nog een abstract van een studie met een virus bij hersentumoren gepubliceerd. Echter het abstract is zo kort dat ik er weinig aan kan toevoegen. Toch lijkt de ontwikkeling van virussen bij hersentumoren een interessant gebied. Zie ook onder abstract studie uit 2006 met virus onder codenaam G-207.

Curr Opin Drug Discov Devel. 2010 Mar;13(2):169-83.

HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases.

Marconi P, Manservigi R, Epstein AL.

Université de Lyon, Université Lyon 1, Lyon F-69003, France. epstein@cgmc.univ-lyon1.fr

Abstract

HSV-1 is a neurotropic virus that displays several important adaptations to the nervous system of the host organism, each of which can be rationally exploited in the design of gene therapy vectors for neurological applications. Replication-incompetent (replication-defective) helper-independent recombinant vectors are nontoxic tools for gene transfer that preserve most of the neurotropic features of HSV-1, particularly the ability to express genes after establishing latent infections, and are thus proficient candidates for therapeutic gene transfer in neurons. A clinical trial with the use of a replication-incompetent vector, NP-2 (Diamyd Inc), for the treatment of pain has been initiated. Attenuated replication-competent (oncolytic) vectors are becoming suitable and powerful tools to eradicate brain tumors, such as malignant gliomas, as a result of the ability to replicate and spread only within the tumor mass. Some attenuated replication-competent vectors, such as G-207 and HSV-1716 (Crusade Laboratories Ltd), have been used in clinical trials for the treatment of cancers including recurrent malignant glioma. Helper-dependent amplicon vector technology takes advantage of the capacity of the virus particle to accommodate < or = 150 Kbp of foreign DNA, enabling these vectors to deliver complete genomic loci to the nucleus of mammalian cells, making amplicons particularly useful agents in protocols that require stable and physiological transgene expression. However, difficulties in obtaining large stocks of helper-free amplicons continue to limit the use of these vectors in the clinic.

PMID: 20205051 [PubMed - indexed for MEDLINE]

9 juni 2005: Bron: DOW met dank aan Karel

Onder de codenaam G 207 is in Amerika een fase I trial geopend met dit virus te injecteren medicijn bij uitbehandelde kankerpatiënten met een kwaadaardige Glioma hersentumor. Er kunnen 20 patiënten aan deze tweejarige studie meedoen. Deze aanpak lijkt op aanpak met Newcastle virus welke aanpak u , mits u zelf betaald , vandaag nog kunt krijgen bij wijze van spreken in Duitsland. Voor adresgegevens van die kliniek kijkt u onder Newcastlevirus informatie

Edited Press Release

FRANKFURT (Dow Jones)--German-U.S. biotech company MediGene AG (MDG.XE) Thursday said it will start clinical trials of cancer-killing virus G207 for the treatment of malignant glioma. MediGene AG, based in Martinsried, Germany and San Diego, U.S., researches and develops treatments for tumor diseases, focusing on high medical need and economic opportunities. G207 is a herpes simplex virus, genetically modified for the specific destruction of tumor cells without harming healthy tissue. Some 20 patients will be enrolled over the next 24 months to take part in the trial, in collaboration with the University of Alabama, Birmingham, USA. The patients suffer from malignant glioma, which is progressive despite radiotherapy and chemotherapy. G207 is one-time administered to these patients, followed by radiation therapy. The trial will evaluate safety, tolerability and efficacy trends of G207 as well as potential synergies with radiation therapy. The study's principal investigator, James M. Markert, M.D., explains: "Previous clinical studies have shown that single doses of G207 administered intra-cerebrally are well tolerated and suggest that G207 may induce tumor regression. In addition, pre-clinical studies indicate synergism between G207 and radiation therapy." Dr. Peter Heinrich, MediGene's Chief Executive Officer, comments: "The study will significantly contribute to the further development of our oncolytic Herpes Simplex Virus program." The commercialization rights will remain with MediGene. Malignant gliomas are the most common brain tumors in adults with 10,000 to 15,000 new cases every year. Treatments such as surgery, radiation and chemotherapy, have extended the survival of patients with these brain tumors from 14 weeks to one year; however, the five year survival rate of glioblastoma multiforme is below 5%. Thus, new treatments for malignant gliomas are needed.

radiotherapie, chemo bestraling, hersentumoren, G-207, virus